|
1
|
Estey EH: Acute myeloid leukemia: 2014
update on risk-stratification and management. Am J Hematol.
89:1063–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen X, Xie H, Wood BL, Walter RB, Pagel
JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR and Estey EH:
Relation of clinical response and minimal residual disease and
their prognostic impact on outcome in acute myeloid leukemia. J
Clin Oncol. 33:1258–1264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fong CY, Grigoriadis G, Hocking J,
Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S,
Patil S, et al: Fludarabine, cytarabine, granulocyte-colony
stimulating factor and amsacrine: an effective salvage therapy
option for acute myeloid leukemia at first relapse. Leuk Lymphoma.
54:336–341. 2013. View Article : Google Scholar
|
|
4
|
Yoon JH, Cho BS, Kim HJ, Kim JH, Shin SH,
Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, et al: Outcomes of elderly
de novo acute myeloid leukemia treated by a risk-adapted approach
based on age, comorbidity, and performance status. Am J Hematol.
88:1074–1081. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH,
Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, et al Korean Society of
Hematology: AML/MDS Working Party: role of induction and
consolidation chemotherapy in elderly acute myeloid leukemia
patients. Int J Hematol. 100:141–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pilatrino C, Cilloni D, Messa E, Morotti
A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo
Coco F, et al: Increase in platelet count in older, poor-risk
patients with acute myeloid leukemia or myelodysplastic syndrome
treated with valproic acid and all-trans retinoic acid. Cancer.
104:101–109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quintás-Cardama A, Santos FP and
Garcia-Manero G: Histone deacetylase inhibitors for the treatment
of myelodysplastic syndrome and acute myeloid leukemia. Leukemia.
25:226–235. 2011. View Article : Google Scholar
|
|
8
|
Bots M, Verbrugge I, Martin BP, Salmon JM,
Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, et
al: Differentiation therapy for the treatment of t(8;21) acute
myeloid leukemia using histone deacetylase inhibitors. Blood.
123:1341–1352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liss A, Ooi CH, Zjablovskaja P, Benoukraf
T, Radomska HS, Ju C, Wu M, Balastik M, Delwel R, Brdicka T, et al:
The gene signature in CCAAT-enhancer-binding protein α
dysfunctional acute myeloid leukemia predicts responsiveness to
histone deacetylase inhibitors. Haematologica. 99:697–705. 2014.
View Article : Google Scholar :
|
|
10
|
Duenas-Gonzalez A, Candelaria M,
Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E and
Herrera LA: Valproic acid as epigenetic cancer drug: preclinical,
clinical and transcriptional effects on solid tumors. Cancer Treat
Rev. 34:206–222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang R, Faussat AM, Majdak P, Perrot JY,
Chaoui D, Legrand O and Marie JP: Valproic acid inhibits
proliferation and induces apoptosis in acute myeloid leukemia cells
expressing P-gp and MRP1. Leukemia. 18:1246–1251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Insinga A, Monestiroli S, Ronzoni S,
Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and
Pelicci PG: Inhibitors of histone deacetylases induce
tumor-selective apoptosis through activation of the death receptor
pathway. Nat Med. 11:71–76. 2005. View
Article : Google Scholar
|
|
13
|
Cencic R, Carrier M, Trnkus A, Porco JA
Jr, Minden M and Pelletier J: Synergistic effect of inhibiting
translation initiation in combination with cytotoxic agents in
acute myelogenous leukemia cells. Leuk Res. 34:535–541. 2010.
View Article : Google Scholar
|
|
14
|
Jiang C, Hu X, Wang L, Cheng H, Lin Y,
Pang Y, Yuan W, Cheng T and Wang J: Excessive proliferation and
impaired function of primitive hematopoietic cells in bone marrow
due to senescence post chemotherapy in a T cell acute lymphoblastic
leukemia model. J Transl Med. 13:2342015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tallarida RJ: Revisiting the isobole and
related quantitative methods for assessing drug synergism. J
Pharmacol Exp Ther. 342:2–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zorzoli A, Di Carlo E, Cocco C, Ognio E,
Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D and
Airoldi I: Interleukin-27 inhibits the growth of pediatric acute
myeloid leukemia in NOD/SCID/Il2rg−/− mice. Clin Cancer
Res. 18:1630–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang C, Hu X, Wang L, Lü S, Cheng H, Song
X, Wang J and Yang J: Bortezomib suppresses the growth of leukemia
cells with Notch1 overexpression in vivo and in vitro. Cancer
Chemother Pharmacol. 70:801–809. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Witt D, Burfeind P, von Hardenberg S,
Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen
J and Kaulfuss S: Valproic acid inhibits the proliferation of
cancer cells by re-expressing cyclin D2. Carcinogenesis.
34:1115–1124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barbetti V, Gozzini A, Cheloni G, Marzi I,
Fabiani E, Santini V, Dello Sbarba P and Rovida E: Time- and
residue-specific differences in histone acetylation induced by VPA
and SAHA in AML1/ETO-positive leukemia cells. Epigenetics.
8:210–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuendgen A, Knipp S, Fox F, Strupp C,
Hildebrandt B, Steidl C, Germing U, Haas R and Gattermann N:
Results of a phase 2 study of valproic acid alone or in combination
with all-trans retinoic acid in 75 patients with myelodysplastic
syndrome and relapsed or refractory acute myeloid leukemia. Ann
Hematol. 84(Suppl 1): 61–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuendgen A, Strupp C, Aivado M, Bernhardt
A, Hildebrandt B, Haas R, Germing U and Gattermann N: Treatment of
myelodysplastic syndromes with valproic acid alone or in
combination with all-trans retinoic acid. Blood. 104:1266–1269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Wang G, Wang L, Kang J and Wang J:
Curcumin p38-dependently enhances the anticancer activity of
valproic acid in human leukemia cells. Eur J Pharm Sci. 41:210–218.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thomas S, Thurn KT, Biçaku E, Marchion DC
and Münster PN: Addition of a histone deacetylase inhibitor
redirects tamoxifentreated breast cancer cells into apoptosis,
which is opposed by the induction of autophagy. Breast Cancer Res
Treat. 130:437–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sung ES, Kim A, Park JS, Chung J, Kwon MH
and Kim YS: Histone deacetylase inhibitors synergistically
potentiate death receptor 4-mediated apoptotic cell death of human
T-cell acute lymphoblastic leukemia cells. Apoptosis. 15:1256–1269.
2010. View Article : Google Scholar : PubMed/NCBI
|
